JNCCN 360

Advertisement

Advertisement

Ruqin Chen, MB, on Lung Cancer Treated With Immune Checkpoint Inhibitors: Predicting Survival Outcomes

Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma

Alexander M.M. Eggermont, MD, PhD, on Adjuvant Therapy for High-Risk Melanoma

Recent

Dual-Target CAR T-Cell Therapy in Resistant Multiple Myeloma

NCI-MATCH Trial Subprotocol: T-DM1 in HER2-Positive Salivary Gland Tumors

Priority Review Granted by FDA to Immunotherapy Combination in Lung Cancer

FDA Grants Priority Review to Olaparib/Bevacizumab as Maintenance Therapy for Ovarian Cancer

Published

Medical Literature

Monoclonal Antibody Combination Under Study in Rare Metastatic Kidney Cancer

Is Combined Checkpoint Blockade Effective in Treating Uveal Melanoma?

Everolimus Plus Bevacizumab in Recurrent Ovarian Cancer

Combination of Rituximab and High-Dose Methylprednisolone for High-Risk Patients With CLL

Ongoing

Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer

The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?

The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?

The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?

Available

Clinical Trials

Cancer Research Institute Immunotherapy Clinical Trials

Center for Immunotherapy Clinical Research Trials

ClinicalTrials.gov Immunotherapy

Immunotherapy Clinical Trials at Fred Hutch Cancer Research Center

NCCN Resources

Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.